|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM34378288X |
003 |
DE-627 |
005 |
20231226021241.0 |
007 |
cr uuu---uuuuu |
008 |
231226s2022 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.3928/23258160-20220615-01
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1145.xml
|
035 |
|
|
|a (DE-627)NLM34378288X
|
035 |
|
|
|a (NLM)35858229
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Greenlee, Tyler E
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Association of Socioeconomic Health Care Disparities With Use of Anti-Vascular Endothelial Growth Factor and Visual Acuity Outcomes in Patients With Diabetic Macular Edema
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 22.07.2022
|
500 |
|
|
|a Date Revised 10.08.2022
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a BACKGROUND AND OBJECTIVE: This study characterizes the impact of race, ethnicity, insurance status, and geographic location on anti-vascular endothelial growth factor (VEGF) use for the treatment of diabetic macular edema (DME)
|
520 |
|
|
|a PATIENTS AND METHODS: This study is a retrospective cohort study. The American Academy of Ophthalmology Intelligent Research in Sight Registry was queried for patients diagnosed with DME who received at least one anti-VEGF injection between 2012 and 2020 (n = 203,707). Multivariate regression analyses investigated associations between race, ethnicity, insurance status, and geographic location and anti-VEGF use and visual outcomes
|
520 |
|
|
|a RESULTS: White race, non-Hispanic/Latino ethnicity, and private insurance were associated with higher use of anti-VEGF injections during a 60-month period (incidence rate ratio, 1.2, 1.25, and 1.17, respectively; P < .01). Furthermore, being of non-Hispanic/Latino ethnicity and having private health insurance were associated with higher longitudinal visual acuity (odds ratio, 1.44 [P = .02] and odds ratio, 1.43 [P < .01], respectively)
|
520 |
|
|
|a CONCLUSION: Ethnicity and insurance status are associated with anti-VEGF use and visual acuity outcomes in DME. [Ophthalmic Surg Lasers Imaging Retina 2022; 53:380-391.]
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
650 |
|
7 |
|a Endothelial Growth Factors
|2 NLM
|
650 |
|
7 |
|a Ranibizumab
|2 NLM
|
650 |
|
7 |
|a ZL1R02VT79
|2 NLM
|
700 |
1 |
|
|a Malhotra, Nisha A
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Iyer, Amogh I
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Conti, Thais F
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chen, Andrew X
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Singh, Rishi P
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 53(2022), 7 vom: 20. Juli, Seite 380-391
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
773 |
1 |
8 |
|g volume:53
|g year:2022
|g number:7
|g day:20
|g month:07
|g pages:380-391
|
856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20220615-01
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_63
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_69
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_90
|
912 |
|
|
|a GBV_ILN_91
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_135
|
912 |
|
|
|a GBV_ILN_136
|
912 |
|
|
|a GBV_ILN_151
|
912 |
|
|
|a GBV_ILN_181
|
912 |
|
|
|a GBV_ILN_203
|
912 |
|
|
|a GBV_ILN_217
|
912 |
|
|
|a GBV_ILN_235
|
912 |
|
|
|a GBV_ILN_289
|
912 |
|
|
|a GBV_ILN_294
|
912 |
|
|
|a GBV_ILN_297
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_352
|
912 |
|
|
|a GBV_ILN_674
|
912 |
|
|
|a GBV_ILN_676
|
912 |
|
|
|a GBV_ILN_688
|
912 |
|
|
|a GBV_ILN_698
|
912 |
|
|
|a GBV_ILN_721
|
912 |
|
|
|a GBV_ILN_737
|
912 |
|
|
|a GBV_ILN_791
|
912 |
|
|
|a GBV_ILN_812
|
951 |
|
|
|a AR
|
952 |
|
|
|d 53
|j 2022
|e 7
|b 20
|c 07
|h 380-391
|